Peters SA, Kley RA (2019) Toxic and drug-induced myopathies. Clinical scenario and imaging. In: Barkhof F, Jäger HR, Thurnher MM, Rovira A (eds) Clinical neuroradiology - the ESNR textbook. Springer Nature
Khefli A, Azzouz M, Abtroun R et al (2016) Myopathies toxiques: vue d’ensemble. Toxicol Analyt Clin 28:187–199
Doughty CT, Amato AA (2019) Toxic myopathies. Continuum (Minneap Minn) 25:1712–1731
Khefli A, Azzouz M, Abtroun R et al (2017) Exploration des myopathies toxiques: de l’anamnèse aux méthodes de pharmacogénomique. Toxicol Analyt Clin 29:273–297
Wattjes MP, Fisher DS (2013) Neuromuscular imaging. Springer, New York
Hooijmans MT, Schlaffke L, Bolsterlee B et al (2023) Compositional and functional MRI of skeletal muscle: a review. J Magn Reson Imaging. https://doi.org/10.1002/jmri.29091
Bowden DH, Fraser D, Jackson SH et al (1956) Acute recurrent rhabdomyolysis (paroxysmal myohaemoglobinuria); a report of three cases and a review of the literature. Medicine (Baltimore) 35:335–353
Article CAS PubMed Google Scholar
Coco TJ, Klasner AE (2004) Drug-induced rhabdomyolysis. Curr Opin Pediatr 16:206–210
Du Souich P, Roederer G, Dufour R (2017) Myotoxicity of statins: mechanism of action. Pharmacol Ther 175:1–16
Ho CK, Walker SW (2012) Statins and their interactions with other lipid-modifying medications: safety issues in the elderly. Ther Adv Drug Saf 3:35–46
Article PubMed PubMed Central Google Scholar
Tournadre A (2020) Statins, myalgia, and rhabdomyolysis. Joint Bone Spine 87:37–42
Article CAS PubMed Google Scholar
Silva M, Matthews ML, Jarvis C et al (2007) Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther 29:253–260
Article CAS PubMed Google Scholar
Chérin P (2014) Myopathies aux statines. NPG Neurol Psychiatr Geriatr 14:11–16
Joy TR, Hegele RA (2009) Narrative review: statin-related myopathy. Ann Intern Med 150:858–868
Watanabe Y, Uruha A, Suzuki S et al (2016) Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry 87:1038–1044
Allenbach Y, Benveniste O, Stenzel W et al (2020) Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol 16:689–701
Article CAS PubMed Google Scholar
Tiniakou E, Pinal-Fernandez I, Lloyd TE et al (2017) More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase-associated autoimmune myopathy. Rheumatology (Oxford) 56:787–794
Wang D, Wang Y (2018) Fenofibrate monotherapy-induced rhabdomyolysis in a patient with hypothyroidism: a rare case report and literature review. Medicine (Baltimore) 97:e0318
Pierce LR, Wysowski DK, Gross TP (1990) Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 264:71–75
Article CAS PubMed Google Scholar
Sauvaget F, Piette JC, Herson S et al (1991) Polymyosite induite par le fénofibrate. Rev Med Interne 12:52–54
Article CAS PubMed Google Scholar
Litin SC, Anderson CF (1989) Nicotinic acid-associated myopathy: a report of three cases. Am J Med 86:481–483
Article CAS PubMed Google Scholar
Slim H, Thompson PD (2008) Ezetimibe-related myopathy: a systematic review. J Clin Lipidol 2:328–334
Prasad GV, Wong T, Meliton G et al (2002) Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation 74:1200–1201
Gürgöze MT, Muller-Hansma AHG, Schreuder MM et al (2019) Adverse events associated with PCSK9 inhibitors: a real-world experience. Clin Pharmacol Ther 105:496–504
Ding L, Chen C, Yang Y et al (2022) Musculoskeletal adverse events associated with PCSK9 inhibitors: disproportionality analysis of the FDA adverse event reporting system. Cardiovasc Ther 2022:9866486
Article PubMed PubMed Central Google Scholar
Banach M, Duell PB, Gotto AM Jr et al (2020) Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia. JAMA Cardiol 5:1124–1135
Cushing H (1932) The basophil adenoma of the pituitary body and their clinical manifestation. Johns Hopkins Med J 50:137–195
Alshekhlee A, Kaminski HJ, Ruff RL (2002) Neuromuscular manifestations of endocrine disorders. Neurol Clin 20(35–58):v–vi
Schakman O, Gilson H, Thissen JP (2008) Mechanisms of glucocorticoid-induced myopathy. J Endocrinol 197:1–10
Article CAS PubMed Google Scholar
Gupta A, Gupta Y (2013) Glucocorticoid-induced myopathy: pathophysiology, diagnosis, and treatment. Indian J Endocrinol Metab 17:913–916
Article PubMed PubMed Central Google Scholar
Pereira RM, Freire de Carvalho J (2011) Glucocorticoid-induced myopathy. Joint Bone Spine 78:41–44
Article CAS PubMed Google Scholar
Hanson P, Dive A, Brucher JM et al (1997) Acute corticosteroid myopathy in intensive care patients. Muscle Nerve 20:1371–1380
Article CAS PubMed Google Scholar
Janssens S, Decramer M (1989) Corticosteroid-induced myopathy and the respiratory muscles. Report of two cases. Chest 95:1160–1162
Article CAS PubMed Google Scholar
Decramer M, de Bock V, Dom R (1996) Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 153:1958–1964
Article CAS PubMed Google Scholar
Askari A, Vignos PJ Jr, Moskowitz RW (1976) Steroid myopathy in connective tissue disease. Am J Med 61:485–492
Article CAS PubMed Google Scholar
Mitsui T, Azuma H, Nagasawa M et al (2002) Chronic corticosteroid administration causes mitochondrial dysfunction in skeletal muscle. J Neurol 249:1004–1009
Article CAS PubMed Google Scholar
Khaleeli AA, Edwards RH, Gohil K et al (1983) Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol (Oxf) 18:155–166
Comments (0)